Andrew Obenshain
Chief Executive Officer bei BLUEBIRD BIO, INC.
Vermögen: 358 397 $ am 31.03.2024
Profil
Andrew Obenshain is currently the President, Chief Executive Officer & Director at bluebird bio, Inc. since 2021.
He is also currently serving as a Director at bluebird bio (UK) Ltd.
since 2017.
Previously, he worked as the General Manager-Finance at Shire France SAS.
Mr. Obenshain completed his undergraduate degree at Dartmouth College and holds an MBA from Kellogg School of Management.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
BLUEBIRD BIO, INC.
0,15% | 04.03.2024 | 279 998 ( 0,15% ) | 358 397 $ | 31.03.2024 |
Aktive Positionen von Andrew Obenshain
Unternehmen | Position | Beginn |
---|---|---|
BLUEBIRD BIO, INC. | Chief Executive Officer | 04.11.2021 |
bluebird bio (UK) Ltd.
bluebird bio (UK) Ltd. BiotechnologyHealth Technology Founded in 2016, bluebird bio (UK) Ltd. is a British biotechnology company that engages in research and development. The private company is based in Basingstoke, UK and is a subsidiary of bluebird bio, Inc. | Director/Board Member | 30.03.2017 |
Ehemalige bekannte Positionen von Andrew Obenshain
Unternehmen | Position | Ende |
---|---|---|
Shire France SAS
Shire France SAS Pharmaceuticals: MajorHealth Technology Shire France SA manufactures pharmaceutical products. The firm offers prescriptions and proprietary drugs. It specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, and genetic diseases. The company was founded in 1997 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Ausbildung von Andrew Obenshain
Dartmouth College | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Shire France SAS
Shire France SAS Pharmaceuticals: MajorHealth Technology Shire France SA manufactures pharmaceutical products. The firm offers prescriptions and proprietary drugs. It specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, and genetic diseases. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
bluebird bio (UK) Ltd.
bluebird bio (UK) Ltd. BiotechnologyHealth Technology Founded in 2016, bluebird bio (UK) Ltd. is a British biotechnology company that engages in research and development. The private company is based in Basingstoke, UK and is a subsidiary of bluebird bio, Inc. | Health Technology |